• news.cision.com/
  • ChemoTech/
  • Scandinavian ChemoTech AB receives final injunction on EU patent for its technology platform for dynamic electroporation

Scandinavian ChemoTech AB receives final injunction on EU patent for its technology platform for dynamic electroporation

Report this content

ChemoTech has received a 71(3), also called final injunction, from the European Patent Office, which announces that one of the company's European patent applications will be approved.

The patent, to which the final injunction applies, covers both the unique design and functionality of the hand probe and the unique treatment kit. This patent also includes the technology that makes the TSE pulses rotate between the different electrodes. This function means that the TSE treatment reduces the risk of cancer cells surviving the treatment due to so-called "Cold Spots" (tissue not reached by the electroporation).

"It is very gratifying to have this EU patent approved which shows the technical height of ChemoTech's TSE platform. This approval gives both ChemoTech's human and veterinary operation the important protection needed for both the commercial establishment in the EU and it also attracts potential partners for distribution and / or licensing agreements. " - says ChemoTech's CEO Mohan Frick

This disclosure contains information that Scandinavian ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on Monday 21st of December 2020 at 11.45 (CET).

For more information, please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00


Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00E-mail: info@penser.se

Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, tumour specific electroporation, available for treatment of both for humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where tumour specific electroporation can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.